SPP Closes Oversubscribed

NZX/ASX Announcement
1 July 2025

Share Purchase Plan Closes Oversubscribed

Truscreen Group Limited (NZX/ASX:TRU) advises that the Share Purchase Plan (SPP) announced on 29 May
2025 closed oversubscribed raising ~NZ$1.67 million (~83 million shares at NZ$0.02).
Together with the share Placement (see NZX/ASX announcement dated 3 June 2025) the Company raised ~$4
million, before costs.
The issue price of the SPP shares was NZ$0.02/A$0.01818, as outlined in the SPP Offer booklet being a 2.5%
discount to the 5 day VWAP pre closure of the SPP.
As both the Placement and SPP subscriptions were in excess of the Company’s capacity, a shareholder meeting
will be held on 15 July 2025 to approve the issue of:
- Up to 26,363,636 shares under the Placement – Listing Rule 4.2
- 28,191,169 shares under the SPP – Listing Rule 4.2
Shareholder approval is also being sought for the issue of share Options attaching to each of the Placement
and SPP shares, as outlined in the Notice of Meeting lodged with the NZX on 30 June 2026.
The successful capital raising was advised by SP Corporate Advisory Pty Limited, and joint lead managed by
S P Corporate Pty Limited and GBA Capital Limited.
Funds raised will be allocated to:
• Growing and increasing TruScreen’s presence in the Chinese market;
• Distribution of Dalton Bio IVD HPV DNA products;
• Executing public cervical cancer screening programs in Vietnam, Zimbabwe and Uzbekistan;
• Continued development of the growing public cervical cancer screening sales channel with key NGOs
and Ministries of Health;
• Development of Indonesian and ASEAN markets;
• Development of the Indian market; and
• Providing additional working capital.

Tony Ho, Chairman commented ”we are extremely pleased with the success of the capital raise and the support
of existing and new shareholders. The funds raised will enable us to capitalise on the significant opportunities
we have and to execute the initiatives we have in place to drive the business to profitability.
We look forward to updating our shareholders on our journey to eliminate cervical cancer.”
Please note: the Shareholder meeting will be held on 15 July 2025 at 11am NZST online only at:
www.virtualmeeting.co.nz/trusm25
This announcement has been approved by the Board.
Ends
Guy Robertson
Company Secretary
Tel: +61 407 983 270
Email: guyrobertson@truscreen.com

For more information, visit www.truscreen.com or contact:

Mr Martin Dillon
Chief Executive Officer
martindillon@truscreen.com



Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com




About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is typically registered as a primary screening device for cervical
cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS
(Mexico). It has Ministry of Health approval for use in Vietnam, Israel and the Philippines, among others
and has distributors in over 20 countries. In 2021, TruScreen established a manufacturing facility in
China for devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical
Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized
Prevent and Treatment” published on 28 April 2023.
In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National
Technical List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the
Russian guidelines for the screening of cervical cancer.
In financial year 2025 alone, approximately 150,000
1
examinations were performed with the
TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico,
Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world without the cervical cancer”
©
.
To learn more, please visit: www.truscreen.com/.
1
Based on Single Use Sensor sales.